Back

Clinical findings and outcomes of Brugada syndrome in women

7 April 2024 (13:30 - 14:15)
Organised by: Logo
Congress Presentation Part of: Arrhythmias 3: atrial fibrillation Ion Channel Disorders EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Mathieu Kruska

University Medical Centre of Mannheim, Mannheim (Germany)

7 More presentations in this session

Presentation thumbnail
Unfolding the transition ratio: insight into the diagnostic criteria for the diagnosis of the origin of outflow tract ventricular arrhythmias.
Doctor L. Lazzari (Terni, IT)
Abstract Slides Video
Presentation thumbnail
Feasibility and diagnostic yield of a photoplethysmography-based arrhythmia screening and integrated management pathway in a chronic obstructive pulmonary disease outpatient clinic
Miss M. Hereijgers (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Photoplethysmography recordings preceding onset atrial fibrillation show a higher heart rate variability - a TeleCheck-AF subanalysis
Doctor H. Hillmann (Hannover, DE)
Abstract Slides Video
Presentation thumbnail
Impact of Pirfenidone on arrhythmic and clinical outcomes in patients with idiopathic pulmonary fibrosis
Doctor S. Im (Pusan, KR)
Abstract Slides Video
Presentation thumbnail
Diagnostic accuracy of smartwatches for automated atrial fibrillation detection over time: insights from the basel wearable study
Ms C. Isenegger (Basel, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Arrhythmias 3: atrial fibrillation

The Event

Event poster

EHRA 2024

7 April 2024 13:30 CET
You may be interested in
thumbnail
Congress Presentation
Clinical aspects of female patients with Brugada syndrome: results from a nationwide multicenter study in Japan
thumbnail
Congress Session
Specific intervention for cardiovascular disease in women
thumbnail
Congress Presentation
Gender differences in risk of sudden cardiac arrest in patients with newly diagnosed non-ischemic cardiomyopathy or coronary artery disease: targeted insights from the SCD-PROTECT study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources